


IRW

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: \_\_\_\_\_ Name: \_\_\_\_\_ Signature: \_\_\_\_\_



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of Andrea Savarino

Serial No.: 10/783,268

Filing Date: February 20, 2004

For: Methods for Treatment of HIV or Malaria Using  
Combinations of Chloroquine and Protease Inhibitors

) Confirmation No.: 7328  
)  
) Group Art Unit: 1617  
)  
) Docket No.: 97728.00147  
)  
) Customer No.: 21832  
)  
)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

In accordance with 37 C.F.R. §1.56, the materials listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. This Information Disclosure Statement is believed to be filed prior to the mailing date of a First Office Action regarding the above-referenced application. Accordingly, no fee is believed to be required. Copies of non-patent references set forth and cited on form PTO/SB/08 are enclosed herewith.

It is respectfully requested the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

In accordance with 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made; an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b); or an admission that the information cited in the statement is, or is considered to be, prior art.

No fee is believed to be required. However, if any fee is required, or otherwise if necessary to cover any deficiency in fees already paid, authorization is hereby given to charge our Deposit Account No. 50-1402.

Respectfully submitted,


Date: 8/3/05

By: Bryan Zerhusen  
Bryan Zerhusen  
Agent for Applicants  
Registration No. 54,566

PTO Correspondence Address:

McCarter & English, LLP  
CityPlace I  
185 Asylum Street  
Hartford, CT 06103  
Phone: (860) 275-6735  
Fax: (860) 724-3397

HARTFORD: 645644.01



PTO/SB/08A (08-03)  
 Approved for use through 07/31/2006. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/783,268
				Filing Date	02/20/04
				First Named Inventor	Savarino, Andrea
				Art Unit	1617
				Examiner Name	To be assigned
				Attorney Docket Number	97728.00147
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	SAVARINO, A. et al., The anti-HIV-1 activity of chloroquine. <i>Journal of Clinical Virology</i> , 20:131-135 (2001). Elsevier Science.	
	2.	SAVARINO, A., et al., Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. <i>Aids</i> , 15:2221-2229 (2001). Lippincott Williams & Wilkins.	
	3.	SAVARINO, A., et al., Anti-HIV Effects of Chloroquine. <i>Journal of Acquired Immune Deficiency Syndrome</i> , 35(3):223-232 (2004). Lippincott Williams & Wilkins.	
	4.	SIDHU, A., et al., Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcr Mutations. <i>Science</i> , Oct. 4, 298:210-213 (2002).	
	5.	SAVARINO, A., et al., Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB</i> , Jan 22, 10.1096/fj.02-0512fje. (2003).	
	6	MAMMANO, F., et al., Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type I Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug. <i>Journal of Virology</i> , 74(18): 8524-8531 (2000).	
	7.	NATHOO, S., et al., Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. <i>The Lancet</i> , Sept. 27, 362:1039-1041 (2003).	
	8.	WARD, SA. Bray, PG., Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum. <i>Drug Resistance Updates</i> , April, 3(2): 80-81 (2000).	
	9.	MAKLER, MT, et al., Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. <i>Am J Trop Med Hyg.</i> , Jun; 48(6):739-741 (1993).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*